je.st
news
Tag: presentation data
Data Needs Presentation 12-19-2017
2018-03-30 17:31:24| PortlandOnline
PDF Document, 1,256kbCategory: April 3, 2018
Tags: data
presentation
data presentation
presentation data
MWESB Performance Data Presentation
2017-07-29 01:41:40| PortlandOnline
PDF Document, 169kbCategory: October
Tags: data
performance
presentation
performance data
PHB MWESB Performance Data Presentation
2016-09-30 18:35:05| PortlandOnline
PDF Document, 169kbCategory: October
Tags: data
performance
presentation
phb
PRESENTATION -- Preliminary Data Analysis and Best Practices
2015-12-11 23:24:58| PortlandOnline
PDF Document, 3,098kbCategory: Vision Zero Task Force Meeting #2: Goals & Policies (11/5/15)
Tags: best
data
analysis
presentation
Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014
2014-09-29 11:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. KEYTRUDA monotherapy achieved 24 percent overall response rate in patients with PD-L1 positive, advanced bladder (urothelial) cancer Planned Phase 3 study in advanced bladder cancer to be initiated by the end of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data on the investigational use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in PD-L1 positive, advanced urothelial cancer (also known as bladder cancer). Language: English Contact: MerckMedia:Ian McConnell, 973-901-5722Claire Mulhearn, 908-423-7425orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
data
advanced
early